Olix Pharmaceuticals Forges Global Partnerships with Eli Lilly adn L’Oréal, Advances RNAi Pipeline
SEOUL, September 16, 2025 – south Korean pharmaceutical firm Olix Pharmaceuticals is rapidly expanding its global reach through strategic alliances with industry giants Eli Lilly and L’Oréal, while concurrently demonstrating promising clinical trial results for its RNA interference (RNAi) drug pipeline.The company announced today a series of advancements across its key therapeutic areas, including obesity, metabolic disease, macular degeneration, and hair loss.
Olix’s aggressive expansion strategy positions the company as a rising force in the RNAi therapeutics space. CEO Lee Dong-gi revealed that a technology transfer contract with Eli Lilly, the world’s largest pharmaceutical company, was signed in February of this year. Joint research with L’Oréal, the global leader in beauty, commenced in June.These partnerships signal growing confidence in Olix’s innovative platform technology and its potential to address significant unmet medical needs.
Clinical trials for Olix’s obesity and metabolic disease drug, OLX702A, developed in collaboration with Eli Lilly, have yielded significant results. According to Lee, the drug demonstrated a 60-80% reduction in liver fat, sustained for over 10 months. He further stated that combining OLX702A with GLP-1-based drugs like Semaglutide amplified weight and abdominal fat reduction.
Beyond Lilly, Olix is also cultivating relationships within the Chinese pharmaceutical market, having entered a platform cooperation agreement with Han so Pharm in 2021 to jointly develop treatments for cardiovascular and metabolic diseases.
Olix’s pipeline extends beyond metabolic disorders. Its macular degeneration drug, OLX301A, designed to treat both wet and dry forms of the disease, is garnering attention, with ongoing discussions with global pharmaceutical companies regarding potential commercialization. Phase 1 clinical trials for OLX104C, a hair loss treatment, have been completed in Australia, with plans to initiate Phase 2A trials imminently. The company is also exploring RNAi applications in the muscle sector,focusing on age-related conditions and potential supplementation of glucagon-like peptide-1 (GLP-1).
